Shiga toxin-associated hemolytic uremic syndrome Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

No FDA or trial events recorded yet for Shiga toxin-associated hemolytic uremic syndrome.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Patient Assistance Programs1

Xifaxan

Salix Pharmaceuticals, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Xifaxan

(rifaximin)Orphan drugstandard

Salix Pharmaceuticals, Inc.

Rifamycin Antibacterial [EPC]

12.1 Mechanism of Action Rifaximin is an antibacterial drug [see Clinical Pharmacology ( 12.4 )].

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Shiga toxin-associated hemolytic uremic syndrome.
Search all trials →

Search clinical trials for Shiga toxin-associated hemolytic uremic syndrome →

Recent News & Research

No recent news articles indexed yet for Shiga toxin-associated hemolytic uremic syndrome.
Search PubMed for Shiga toxin-associated hemolytic uremic syndrome →

Browse all Shiga toxin-associated hemolytic uremic syndrome news →

Specialist Network

Top 2 by expertise

Santiago Sanguineti, Ph.D

Inmunova S.A.

Score 261 trial

Fernando Goldbaum, PhD

Inmunova S.A.

Score 171 trial

View all Shiga toxin-associated hemolytic uremic syndrome specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰